Business context and reporting period
Concord Medical Services Holdings Limited filed this Form 20-F for the fiscal year ended December 31, 2016. Although the request identifies 2016 Q4, the filing reports full-year results and does not provide a clear standalone fourth-quarter income statement or cash flow. The company operates radiotherapy and diagnostic-imaging centers primarily through hospital partnerships in China, alongside hospital operations in Singapore. Financial statements are prepared under U.S. GAAP; amounts below are RMB unless otherwise noted.
At year-end, the network comprised 95 cooperative centers in 57 hospitals across 49 cities. The company also operated Concord Cancer Hospital in Singapore and was developing cancer hospitals and a proton center in China.
Financial performance and position
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Net revenue | RMB455.0 million | RMB616.5 million |
| Gross profit / margin | RMB168.5 million / 37.0% | RMB263.1 million / 42.7% |
| Operating income (loss) | (RMB168.6 million) | (RMB5.7 million) |
| Net income (loss) | (RMB265.1 million) | (RMB79.3 million) |
| Operating cash flow | (RMB78.1 million) | (RMB175.1 million) |
| Investing cash flow | (RMB74.8 million) | (RMB391.1 million) |
| Financing cash flow | (RMB131.4 million) | RMB590.4 million |
| Cash at year-end | RMB189.9 million | RMB485.4 million |
Revenue fell 26.2%, primarily because cooperative centers were terminated and profit-sharing revenue declined at centers later in their contract terms. Network revenue was RMB443.6 million, or 97.5% of total revenue; Singapore hospital revenue was RMB11.4 million. Treatment cases increased 8.4% year over year, while diagnostic cases fell 11.0%.
Cost of revenue declined 18.9%, less than revenue, contributing to the gross-margin contraction. Operating expenses rose 25.4% to RMB337.1 million: selling expense fell to RMB70.1 million, while general and administrative expense rose to RMB205.9 million, attributed mainly to new hospital operations and establishment of a Singapore office. The company recorded RMB61.1 million of long-lived-asset impairment. Interest expense increased to RMB89.3 million; income-tax expense was RMB60.5 million despite a pretax loss.
At December 31, 2016, cash was RMB189.9 million and current assets were RMB1,194.9 million against current liabilities of RMB951.1 million, yielding reported net current assets of RMB243.8 million. Bank and other borrowings totaled RMB860.7 million, plus RMB328.2 million of secured borrowings; restricted cash was RMB568.5 million. Total liabilities were RMB1,996.8 million and total equity RMB1,231.8 million. Network receivables were RMB188.7 million; average network receivable turnover was 165 days.
Material changes, outlook, and risks
- Revenue and profitability weakened materially: FY 2016 revenue fell 26.2%, gross margin declined 5.7 percentage points, and net loss widened by RMB185.8 million. Operating cash use improved from FY 2015 but remained negative.
- Management said cash and anticipated operating cash flow should cover working capital and capital expenditures for at least 12 months. It reported RMB1.5 billion of unused bank credit lines at year-end.
- Management estimated 2017 capital expenditures of RMB600–800 million, including approximately RMB590 million for proton-center and premium-hospital construction. It separately estimated RMB150–250 million annually for planned specialty-hospital expansion, with roughly 70% of hospital-project funding expected from bank loans and 30% from operating cash flow. These estimates’ scope and overlap are not clear in the filing.
- The company intended to open three to five specialty cancer hospitals annually over the following three years. Construction of the Beijing proton center and Shanghai and Guangzhou hospitals was expected to begin in 2017; timing, approvals, funding, staffing, patient demand, and commercial-insurance coverage remain execution risks.
- Revenue is concentrated: the top five hospital partners contributed 27.7% of FY 2016 revenue. Twenty lease-and-management contracts were due to expire in 2017; those centers generated 30.4% of FY 2016 revenue. Two of 95 equipment units subject to procurement-license requirements lacked a license or interim permit at year-end.
- Other material risks include healthcare regulation and price controls in China, hospital-partner payment delays, dependence on qualified medical professionals and equipment suppliers, foreign-exchange and interest-rate exposure, and substantial capital needs. The company reported no material litigation.
- In July 2016, controlling shareholders made a nonbinding going-private proposal at US$5.19 per ADS; the filing does not report a completed transaction. A February 2017 strategic fund arrangement and planned investment in hospital assets are subsequent events, not FY 2016 operating results.
Governance, controls, and unusual items
The financial-statement auditor issued an unqualified opinion on the FY 2016 U.S. GAAP statements. However, management and the auditor concluded that internal control over financial reporting was ineffective due to a material weakness in controls for identifying and measuring impairment of leased equipment. Management targeted remediation for the second half of 2017; effectiveness had not yet been demonstrated.
The company paid RMB285.8 million of dividends during 2016, relating to a special dividend declared in December 2015, and repurchased shares for RMB30.4 million. No special dividend was declared in 2016. The filing also disclosed a 9% related-party loan from an entity controlled by a company director, with RMB172.6 million outstanding at year-end.
Important facts for investors to verify
- Whether 2017 capital-expenditure estimates are consistent in scope, and whether funding and credit availability support the stated construction plans.
- Renewal or termination outcomes for the 20 contracts due to expire in 2017, and progress collecting the RMB188.7 million of network receivables.
- Whether the impairment-control material weakness was remediated and independently tested, and the assumptions supporting future impairment assessments.
- Current status and terms of the going-private proposal, the dual-class voting structure, and subsequent fund or hospital transactions.
- Liquidity available after considering restricted cash, debt maturities, debt-service costs, and the company’s continuing operating cash outflows.